Characteristics of lung cancer among patients with idiopathic pulmonary fibrosis and interstitial lung disease – analysis of institutional and population data-Reference-Cited by-同舟云学术

Characteristics of lung cancer among patients with idiopathic pulmonary fibrosis and interstitial lung disease – analysis of institutional and population data

Published:2018-10-03 Issue:1 Volume:19 Page:
ISSN:1465-993X
Container-title:Respiratory Research
language:en
Short-container-title:Respir Res

Author:

Yoon Joo Heung^ORCID,Nouraie Mehdi,Chen Xiaoping,Zou Richard H,Sellares Jacobo,Veraldi Kristen L,Chiarchiaro Jared,Lindell Kathleen,Wilson David O,Kaminski Naftali,Burns Timothy,Trejo Bittar Humberto,Yousem Samuel,Gibson Kevin,Kass Daniel J

Funder

National Institutes of Health

Publisher

Springer Science and Business Media LLC

Link

http://link.springer.com/content/pdf/10.1186/s12931-018-0899-4.pdf

Reference41 articles.

1. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King TE Jr, Kondoh Y, Myers J, Muller NL, Nicholson AG, Richeldi L, Selman M, Dudden RF, Griss BS, Protzko SL, Schunemann HJ, Fibrosis AEJACIP. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788–824.

2. Ley B, Collard HR. Epidemiology of idiopathic pulmonary fibrosis. Clin Epidemiol. 2013;5:483–92.

3. King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L, Lederer DJ, Nathan SD, Pereira CA, Sahn SA, Sussman R, Swigris JJ, Noble PW, Group AS. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2083–92.

4. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y, Kim DS, Kolb M, Nicholson AG, Noble PW, Selman M, Taniguchi H, Brun M, Le Maulf F, Girard M, Stowasser S, Schlenker-Herceg R, Disse B, Collard HR, Investigators IT. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2071–82.

5. Wuyts WA, Cavazza A, Rossi G, Bonella F, Sverzellati N, Spagnolo P. Differential diagnosis of usual interstitial pneumonia: when is it truly idiopathic? Eur Respir Rev. 2014;23:308–19.

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fibrosis to carcinogenesis: unveiling the causal dynamics between pulmonary fibrosis and lung cancer;Frontiers in Oncology;2024-08-16

2. Lung Cancer and Interstitial Lung Diseases;Cancers;2024-08-13

3. Combined expert-in-the-loop—random forest multiclass segmentation U-net based artificial intelligence model: evaluation of non-small cell lung cancer in fibrotic and non-fibrotic microenvironments;Journal of Translational Medicine;2024-07-08

4. Central Role of CT in Management of Pulmonary Fibrosis;RadioGraphics;2024-06-01

5. Subsolid Nodules;Clinics in Chest Medicine;2024-06